tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Anixa Biosciences treats second patient in fourth ovarian cancer trial cohort

Anixa Biosciences (ANIX) announced that the second patient in the fourth dose cohort has been treated in the ongoing Phase 1 clinical trial evaluating the company’s novel chimeric antigen receptor-T cell therapy for recurrent ovarian cancer. Patients in the fourth cohort are receiving a dose of three million CAR-positive cells per kilogram of body weight-representing a 30-fold increase over the initial dose level. To date, no dose-limiting toxicities have been observed in the fourth cohort. The ongoing first-in-human clinical trial (NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior lines of therapy. The Phase 1 study is designed to evaluate safety, determine the maximum tolerated dose, and monitor initial signals of clinical activity.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1